The FDA issues warnings to 14 companies for marketing illegal cancer remedies
Date: 2017-06-19   Author: Saipriya Iyer  Category: #news

The Food and Drug Administration has notified 14 companies for illegally selling untested products as a viable treatment medication for cancer. Reliable sources state that 14 U.S. based companies have been found to manufacture and sell more than 65 products which apparently claim to diagnose, prevent, or cure the universally dreaded terminal disease - cancer. These products have been developed, marketed, and sold to consumers without the approval of the FDA, which is a clear violation of the FDA norms.

As per the Federal Food, Drug and Cosmetic Act, it is illegal for medical, healthcare, cosmetic, and pharmaceutical companies to market and sell products that claim to prevent, diagnose, or cure diseases without presenting viable evidence of its safety and assurance to the FDA. These companies however, have manufactured creams, oils, syrups, herbal & exotic teas, pills, drops, ointments, and extracts such as that of asparagus and other organic veggies, and falsely declared these products to possess anti-cancerous properties. The companies have extensively marketed these unapproved products on social media and online portals as feasible cures for cancer. Desperate marketing one-liners include ‘selectively kills cancer cells’, ‘shrinks malignant tumors’, ‘treats all forms of cancer’, ‘miraculously kills cancer cells and tumors’, and the like, as per the company websites and promotional adverts, many of which have been prompting desperate consumers to buy these products.

Some of these companies have also reportedly developed diagnostic devices that use digital thermal imaging – thermography, as an alternative to mammography, to diagnose breast cancer. The FDA has declared that many of these thermography devices are unauthorized and unreliable.

FDA officials claim that the lure of buying organic, inexpensive products to cure cancer is likely to prevent a patient from seeking a proper, authorized, potentially life-saving treatment plan. In accordance with the law, the agency has issued warning letters to these 14 companies, ordering them to stop making fraudulent claims or face the disastrous consequences of their illegal actions. These letters comprise more than five unapproved products that are promoted with bogus claims of treating liver disease, arthritis, cancer, or kidney disease. The companies have been requested to comply with the regulations and remove the false claims from their website. Failure to do so is likely to lead to criminal prosecution or product seizure.

This is not the first time the FDA has taken prompt action against fraudulent products. More than 90 letters have been issued to firms manufacturing unapproved products in the last 10 years. Complying with the law, the FDA will continue to evaluate and monitor unproven and untested products to secure consumers from potential dangers.

In a bid to protect vulnerable patients from illegal medication, the FDA has also publicly warned consumers to be cognizant of advertisements promoting natural products as fraudulent treatment drugs. The organization has also cautioned consumers and medical care experts to observe and report any detrimental reactions of the products mentioned above or related ones purchased online to MedWatch, FDA’s Safety Information and Adverse Event Reporting Program.

About Author

Saipriya Iyer

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

More from Saipriya

Post Recommendents

Alibaba prioritizes SEA expansion, pours in USD 2bn more in Lazada
Author: Dhananjay Punekar

Alibaba Group Holding Limited, a Chinese eCommerce & retail firm, is expected to provide an additional investment worth USD 2 billion to Lazada Group SA, an eCommerce firm headquartered in Singapore.  Incident...

Grofers secures USD 61.6 million in funding round led by SoftBank
Author: Dhananjay Punekar

Grofers, an India-based online grocery delivery service, has received funds worth USD 61.6 million from SoftBank Group via its initial fund-raising round. Incidentally, the round also witnessed the participation of Apo...

Mayne Pharma Group launches a generic alternative to Monodox in U.S.
Author: Sunil Hebbalkar

Mayne Pharma Group, the Australia-headquartered drug delivery conglomerate, has recently announced the launch of doxycycline monohydrate IR capsules in the United States. Reportedly, the scarcely launched drug is a gen...